Biocon Of India, Akrikhin Of Russia Sign Transplant-Drug Deal
This article was originally published in PharmAsia News
Executive Summary
Russia's Akrikhin and India's Biocon have agreed to develop a generic drug for use in transplants, with a goal to launch by 2013